Paricalcitol (BioDeep_00000006667)

 

Secondary id: BioDeep_00000638152

human metabolite blood metabolite Chemicals and Drugs


代谢物信息卡片


(1R,3R)-5-{2-[(1R,3aS,4E,7aR)-1-[(2R,3E,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}cyclohexane-1,3-diol

化学式: C27H44O3 (416.3290274)
中文名称: 帕立骨化醇
谱图信息: 最多检出来源 Homo sapiens(urine) 75%

分子结构信息

SMILES: CC(C=CC(C)C(C)(C)O)C1CCC2C(=CC=C3CC(O)CC(O)C3)CCCC21C
InChI: InChI=1S/C27H44O3/c1-18(8-9-19(2)26(3,4)30)24-12-13-25-21(7-6-14-27(24,25)5)11-10-20-15-22(28)17-23(29)16-20/h8-11,18-19,22-25,28-30H,6-7,12-17H2,1-5H3/b9-8+,21-11+/t18-,19+,22-,23-,24-,25+,27-/m1/s1

描述信息

Paricalcitol is only found in individuals that have used or taken this drug. It is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.Paricalcitol is biologically active vitamin D analog of calcitriol with modifications to the side chain (D2) and the A (19-nor) ring. Preclinical andin vitro studies have demonstrated that paricalcitols biological actions are mediated through binding of the VDR, which results in the selective activation of vitamin D responsive pathways. Vitamin D and paricalcitol have been shown to reduce parathyroid hormone levels by inhibiting PTH synthesis and secretion.
H - Systemic hormonal preparations, excl. sex hormones and insulins > H05 - Calcium homeostasis > H05B - Anti-parathyroid agents
D018977 - Micronutrients > D014815 - Vitamins > D004872 - Ergocalciferols

同义名列表

11 个代谢物同义名

(1R,3R)-5-{2-[(1R,3aS,4E,7aR)-1-[(2R,3E,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}cyclohexane-1,3-diol; (1R,3R,7E)-17beta-[(2R,3E,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-9,10-secoestra-5,7-diene-1,3-diol; 19-Nor-1alpha,25-dihydroxyvitamin D2; 19-Nor-1α,25-dihydroxyvitamin D2; 19-Nor-1a,25-dihydroxyvitamin D2; Abbott brand OF paricalcitol; 19-Nor-1,25-(OH)2D2; Paricalcitol-D6; Paricalcitol; FT-0673519; Zemplar



数据库引用编号

17 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Abdulrahman Mujalli, Wesam F Farrash, Ahmad A Obaid, Anmar A Khan, Riyad A Almaimani, Shakir Idris, Mohamed E Elzubier, Elshiekh Babiker A Khidir, Akhmed Aslam, Faisal Minshawi, Mohammad A Alobaidy, Adel B Alharbi, Hussain A Almasmoum, Mazen Ghaith, Khalid Alqethami, Bassem Refaat. Improved Glycaemic Control and Nephroprotective Effects of Empagliflozin and Paricalcitol Co-Therapy in Mice with Type 2 Diabetes Mellitus. International journal of molecular sciences. 2023 Dec; 24(24):. doi: 10.3390/ijms242417380. [PMID: 38139208]
  • Mohamed El-Boshy, Aiman Alsaegh, Ahmed H Qasem, Ramya A Sindi, Abdelghany H Abdelghany, Hossam Gadalla, Doha Reda, Firas Azzeh, Shakir Idris, Jawwad Ahmad, Bassem Refaat. Enhanced renoprotective actions of Paricalcitol and omega-3 fatty acids co-therapy against diabetic nephropathy in rat. Journal of advanced research. 2022 05; 38(?):119-129. doi: 10.1016/j.jare.2021.08.010. [PMID: 35572411]
  • Hina L Nizami, Parmeshwar B Katare, Pankaj Prabhakar, Ramu Adela, Soumalya Sarkar, Sudheer Arava, Praloy Chakraborty, Subir K Maulik, Sanjay K Banerjee. Paricalcitol Attenuates Metabolic Syndrome-Associated Heart Failure through Enhanced Mitochondrial Fusion. Oxidative medicine and cellular longevity. 2022; 2022(?):5554290. doi: 10.1155/2022/5554290. [PMID: 35726330]
  • Niansong Wang, Yuting Xie, Gengru Jiang. Efficacy and safety of intravenous paricalcitol treatment in Chinese hemodialysis patients: a real-world database analysis. Annals of palliative medicine. 2022 Jan; 11(1):225-239. doi: 10.21037/apm-21-3966. [PMID: 35144414]
  • Farhad Koohpeyma, Gholamhossein Ranjbar Omrani, Ali Zamani, Forough Saki. Effects of Paricalcitol on Body Composition in Vitamin D-Deficient Rats. Iranian journal of medical sciences. 2021 11; 46(6):468-474. doi: 10.30476/ijms.2020.85368.1503. [PMID: 34840387]
  • Jing Huang, Qi An, Bo-Miao Ju, Jing Zhang, Ping Fan, Lan He, Lei Wang. Role of vitamin D/VDR nuclear translocation in down-regulation of NF-κB/NLRP3/caspase-1 axis in lupus nephritis. International immunopharmacology. 2021 Nov; 100(?):108131. doi: 10.1016/j.intimp.2021.108131. [PMID: 34536747]
  • Bin Wang, Jing-Yi Qian, Tao-Tao Tang, Li-Lu Lin, Nan Yu, Hong-Lei Guo, Wei-Jie Ni, Ling-Li Lv, Yi Wen, Zuo-Lin Li, Min Wu, Jing-Yuan Cao, Bi-Cheng Liu. VDR/Atg3 Axis Regulates Slit Diaphragm to Tight Junction Transition via p62-Mediated Autophagy Pathway in Diabetic Nephropathy. Diabetes. 2021 11; 70(11):2639-2651. doi: 10.2337/db21-0205. [PMID: 34376476]
  • Raquel Martínez-Pulleiro, María García-Murias, Manuel Fidalgo-Díaz, Miguel Ángel García-González. Molecular Basis, Diagnostic Challenges and Therapeutic Approaches of Alport Syndrome: A Primer for Clinicians. International journal of molecular sciences. 2021 Oct; 22(20):. doi: 10.3390/ijms222011063. [PMID: 34681722]
  • Yue Qu, Yuche Wu, Hong Jiang. Research progress in the pharmacological actions of the multiple effects and selectivity of the vitamin D analogue paricalcitol: a narrative review. Annals of palliative medicine. 2021 10; 10(10):11177-11190. doi: 10.21037/apm-21-2249. [PMID: 34763476]
  • Jeong-Hoon Lim, Ju-Min Yook, Se-Hyun Oh, Soo-Jee Jeon, Hee Won Noh, Hee-Yeon Jung, Ji-Young Choi, Jang-Hee Cho, Chan-Duck Kim, Yong-Lim Kim, Sun-Hee Park. Paricalcitol Improves Hypoxia-Induced and TGF-β1-Induced Injury in Kidney Pericytes. International journal of molecular sciences. 2021 Sep; 22(18):. doi: 10.3390/ijms22189751. [PMID: 34575914]
  • María Dolores Arenas Jimenez, Emilio González-Parra, Marta Riera, Abraham Rincón Bello, Ana López-Herradón, Higini Cao, Sara Hurtado, Silvia Collado, Laura Ribera, Francesc Barbosa, Fabiola Dapena, Vicent Torregrosa, José-Jesús Broseta, Carlos Soto Montañez, Juan F Navarro-González, Rosa Ramos, Jordi Bover, Xavier Nogués-Solan, Marta Crespo, Adriana S Dusso, Julio Pascual. Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics. Nutrients. 2021 Jul; 13(8):. doi: 10.3390/nu13082559. [PMID: 34444716]
  • Hasan Haci Yeter, Berfu Korucu, Elif Burcu Bali, Ulver Derici. Association between calcitriol and paricalcitol with oxidative stress in patients with hemodialysis. International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition. 2021 Jun; 91(3-4):335-342. doi: 10.1024/0300-9831/a000641. [PMID: 32065560]
  • Laura Martínez-Arias, Sara Panizo, Cristina Alonso-Montes, Julia Martín-Vírgala, Beatriz Martín-Carro, Sara Fernández-Villabrille, Carmen García Gil-Albert, Carmen Palomo-Antequera, José Luis Fernández-Martín, María Piedad Ruiz-Torres, Adriana S Dusso, Natalia Carrillo-López, Jorge B Cannata-Andía, Manuel Naves-Díaz. Effects of calcitriol and paricalcitol on renal fibrosis in CKD. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2021 04; 36(5):793-803. doi: 10.1093/ndt/gfaa373. [PMID: 33416889]
  • Fadime Demir, Mustafa Demir, Hatice Aygun. Evaluation of the protective effect of paricalcitol and vitamin D3 at doxorubicin nephrotoxicity in rats with 99mTechnetium-dimercaptosuccinic acid renal scintigraphy and biochemical methods. Human & experimental toxicology. 2021 Feb; 40(2):274-283. doi: 10.1177/0960327120950010. [PMID: 32812453]
  • Siqing Jiang, Hao Zhang, Xin Li, Bin Yi, Lihua Huang, Zhaoxin Hu, Aimei Li, Jie Du, Yanchun Li, Wei Zhang. Vitamin D/VDR attenuate cisplatin-induced AKI by down-regulating NLRP3/Caspase-1/GSDMD pyroptosis pathway. The Journal of steroid biochemistry and molecular biology. 2021 02; 206(?):105789. doi: 10.1016/j.jsbmb.2020.105789. [PMID: 33259938]
  • Zhuolin Zhang, Lele Cai, Hong Wu, Xinglu Xu, Wenqing Fang, Xuan He, Xiao Wang, Xin Li. Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis. Frontiers in public health. 2021; 9(?):712027. doi: 10.3389/fpubh.2021.712027. [PMID: 34368073]
  • Ronald M Evans, Scott M Lippman. Shining Light on the COVID-19 Pandemic: A Vitamin D Receptor Checkpoint in Defense of Unregulated Wound Healing. Cell metabolism. 2020 11; 32(5):704-709. doi: 10.1016/j.cmet.2020.09.007. [PMID: 32941797]
  • Sandra Rayego-Mateos, Jose Luis Morgado-Pascual, José Manuel Valdivielso, Ana Belén Sanz, Enrique Bosch-Panadero, Raúl R Rodrigues-Díez, Jesús Egido, Alberto Ortiz, Emilio González-Parra, Marta Ruiz-Ortega. TRAF3 Modulation: Novel Mechanism for the Anti-inflammatory Effects of the Vitamin D Receptor Agonist Paricalcitol in Renal Disease. Journal of the American Society of Nephrology : JASN. 2020 09; 31(9):2026-2042. doi: 10.1681/asn.2019111206. [PMID: 32631974]
  • Hasan Sözel, Sadi Köksoy, Sebahat Ozdem, Fatih Yılmaz, Feyza Bora, F Fevzi Ersoy. Lymphocyte and monocyte vitamin D receptor expression during paricalcitol or calcitriol treatments in patients with stage 5 chronic kidney disease. International urology and nephrology. 2020 Aug; 52(8):1563-1570. doi: 10.1007/s11255-020-02475-1. [PMID: 32405698]
  • Hatice Aygun, Nursah Basol, Serdar Savas Gul. Cardioprotective Effect of Paricalcitol on Amitriptyline-Induced Cardiotoxicity in Rats: Comparison of [99mTc]PYP Cardiac Scintigraphy with Electrocardiographic and Biochemical Findings. Cardiovascular toxicology. 2020 08; 20(4):427-436. doi: 10.1007/s12012-020-09569-3. [PMID: 32219715]
  • Carlo Massimetti, Antonio Bellasi, Sandro Feriozzi. [Cholecalciferol supplementation improves secondary hyperparathyroidism control in hemodialysis patients]. Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia. 2020 Jun; 37(3):. doi: . [PMID: 32530156]
  • Dangfeng Zhang, Lin Qiao, Ting Fu. Paricalcitol improves experimental autoimmune encephalomyelitis (EAE) by suppressing inflammation via NF-κB signaling. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2020 May; 125(?):109528. doi: 10.1016/j.biopha.2019.109528. [PMID: 32106388]
  • Ravi I Thadhani, Sophia Rosen, Norma J Ofsthun, Len A Usvyat, Lorien S Dalrymple, Franklin W Maddux, Jeffrey L Hymes. Conversion from Intravenous Vitamin D Analogs to Oral Calcitriol in Patients Receiving Maintenance Hemodialysis. Clinical journal of the American Society of Nephrology : CJASN. 2020 03; 15(3):384-391. doi: 10.2215/cjn.07960719. [PMID: 32111702]
  • Laura Salanova Villanueva, Yohana Gil Giraldo, Begoña Santos Sánchez-Rey, Abelardo Aguilera Peralta. Paricalcitol regulatory effect on inflammatory, fibrotic and anticalcificating parameters in renal patiente. Far beyond mineral bone disease regulation. Nefrologia. 2020 Mar; 40(2):171-179. doi: 10.1016/j.nefro.2019.08.001. [PMID: 31740151]
  • Kamyar Kalantar-Zadeh, Christopher S Hollenbeak, Roy Arguello, Sophie Snyder, Akhtar Ashfaq. The cost-effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3-4 CKD. Journal of medical economics. 2020 Mar; 23(3):308-315. doi: 10.1080/13696998.2019.1693385. [PMID: 31726882]
  • Graziella D'Arrigo, Patrizia Pizzini, Sebastiano Cutrupi, Rocco Tripepi, Giovanni Tripepi, Francesca Mallamaci, Carmine Zoccali. FGF23 and the PTH response to paricalcitol in chronic kidney disease. European journal of clinical investigation. 2020 Feb; 50(2):e13196. doi: 10.1111/eci.13196. [PMID: 31863599]
  • Zhaoxin Hu, Hao Zhang, Bin Yi, Shikun Yang, Jun Liu, Jing Hu, Jianwen Wang, Ke Cao, Wei Zhang. VDR activation attenuate cisplatin induced AKI by inhibiting ferroptosis. Cell death & disease. 2020 01; 11(1):73. doi: 10.1038/s41419-020-2256-z. [PMID: 31996668]
  • Xinghua Geng, Ermin Shi, Shiwei Wang, Yuzhi Song. A comparative analysis of the efficacy and safety of paricalcitol versus other vitamin D receptor activators in patients undergoing hemodialysis: A systematic review and meta-analysis of 15 randomized controlled trials. PloS one. 2020; 15(5):e0233705. doi: 10.1371/journal.pone.0233705. [PMID: 32470067]
  • Eunjin Bae, Jin Hyun Kim, Myeong Hee Jung, Si Jung Jang, Tae Won Lee, Sehyun Jung, Seunghye Lee, Ha Nee Jang, Se-Ho Chang, Dong Jun Park. Paricalcitol Attenuates Contrast-Induced Acute Kidney Injury by Regulating Mitophagy and Senescence. Oxidative medicine and cellular longevity. 2020; 2020(?):7627934. doi: 10.1155/2020/7627934. [PMID: 33299530]
  • Hege Kampen Pihlstrøm, Thor Ueland, Annika E Michelsen, Pål Aukrust, Franscesca Gatti, Clara Hammarström, Monika Kasprzycka, Junbai Wang, Guttorm Haraldsen, Geir Mjøen, Dag Olav Dahle, Karsten Midtvedt, Ivar Anders Eide, Anders Hartmann, Hallvard Holdaas. Exploring the potential effect of paricalcitol on markers of inflammation in de novo renal transplant recipients. PloS one. 2020; 15(12):e0243759. doi: 10.1371/journal.pone.0243759. [PMID: 33326471]
  • Nakhoul Nakhoul, Tina Thawko, Evgeny Farber, Inbal Dahan, Hagar Tadmor, Rola Nakhoul, Anaam Hanut, Ghasan Salameh, Ibrahim Shagrawy, Farid Nakhoul. The Therapeutic Effect of Active Vitamin D Supplementation in Preventing the Progression of Diabetic Nephropathy in a Diabetic Mouse Model. Journal of diabetes research. 2020; 2020(?):7907605. doi: 10.1155/2020/7907605. [PMID: 33294462]
  • Alexandra Schuster, Akram Al-Makki, Brian Shepler. Use of Paricalcitol as Adjunctive Therapy to Renin-Angiotensin-Aldosterone System Inhibition for Diabetic Nephropathy: A Systematic Review of the Literature. Clinical therapeutics. 2019 11; 41(11):2416-2423. doi: 10.1016/j.clinthera.2019.09.009. [PMID: 31601446]
  • Yan Liu, Liu Li, Bin Yi, Zhao-Xin Hu, Ai-Mei Li, Cheng Yang, Li Zheng, Hao Zhang. Activation of vitamin D receptor attenuates high glucose-induced cellular injury partially dependent on CYP2J5 in murine renal tubule epithelial cell. Life sciences. 2019 Oct; 234(?):116755. doi: 10.1016/j.lfs.2019.116755. [PMID: 31415769]
  • Cristian Rodelo-Haad, Elvira Esquivias-Motta, Francisco Amaral-Neiva, Alejandro Martin-Malo, Pedro Aljama, Mariano Rodriguez. Reversing extraosseous calcifications. A case of breast uremic calcific arteriolopathy. The breast journal. 2019 09; 25(5):998-999. doi: 10.1111/tbj.13389. [PMID: 31187553]
  • Kristina Lundwall, Josefin Mörtberg, Fariborz Mobarrez, Stefan H Jacobson, Gun Jörneskog, Jonas Spaak. Changes in microparticle profiles by vitamin D receptor activation in chronic kidney disease - a randomized trial. BMC nephrology. 2019 08; 20(1):290. doi: 10.1186/s12882-019-1445-4. [PMID: 31370809]
  • Hasan Koc, Hasan Hoser, Yalcin Akdag, Cemaliye Kendir, F Fevzi Ersoy. Treatment of secondary hyperparathyroidism with paricalcitol in patients with end-stage renal disease undergoing hemodialysis in Turkey: an observational study. International urology and nephrology. 2019 Jul; 51(7):1261-1270. doi: 10.1007/s11255-019-02175-5. [PMID: 31161518]
  • Ming-Chao He, Zhe Shi, Nan-Nan Sha, Nan Chen, Shi-Yu Peng, Duan-Fang Liao, Man-Sau Wong, Xiao-Li Dong, Yong-Jun Wang, Ti-Fei Yuan, Yan Zhang. Paricalcitol alleviates lipopolysaccharide-induced depressive-like behavior by suppressing hypothalamic microglia activation and neuroinflammation. Biochemical pharmacology. 2019 05; 163(?):1-8. doi: 10.1016/j.bcp.2019.01.021. [PMID: 30703351]
  • Jie Du, Siqing Jiang, Zhaoxin Hu, Shiqi Tang, Yue Sun, Jinrong He, Zhi Li, Bin Yi, Jianwen Wang, Hao Zhang, Yan Chun Li. Vitamin D receptor activation protects against lipopolysaccharide-induced acute kidney injury through suppression of tubular cell apoptosis. American journal of physiology. Renal physiology. 2019 05; 316(5):F1068-F1077. doi: 10.1152/ajprenal.00332.2018. [PMID: 30864841]
  • Graziella D'arrigo, Patrizia Pizzini, Sebastiano Cutrupi, Rocco Tripepi, Giovanni Tripepi, Francesca Mallamaci, Carmine Zoccali. Vitamin D receptor activation raises soluble thrombomodulin levels in chronic kidney disease patients: a double blind, randomized trial. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2019 05; 34(5):819-824. doi: 10.1093/ndt/gfy085. [PMID: 29668990]
  • Ricardo Villa-Bellosta, Ignacio Mahillo-Fernández, Alberto Ortíz, Emilio González-Parra. Questioning the Safety of Calcidiol in Hemodialysis Patients. Nutrients. 2019 04; 11(5):. doi: 10.3390/nu11050959. [PMID: 31035488]
  • Joana Gameiro, Inês Duarte, Cristina Outerelo, José António Lopes. Uremic lion face syndrome. Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia. 2019 Apr; 41(2):304-305. doi: 10.1590/2175-8239-jbn-2018-0198. [PMID: 30720853]
  • Michalis Giakoumis, Costas Tsioufis, Kyriakos Dimitriadis, Makro Sonikian, Alexandros Kasiakogias, Eirini Andrikou, Theodoros Kalos, Dimitrios Konstantinidis, Konstantinos Filis, Dimitrios Petras, Dimitrios Tousoulis. Effects of oral paricalcitol therapy on arterial stiffness and osteopontin in hypertensive patients with chronic kidney disease and secondary hyperparathyroidism. Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese. 2019 Mar; 60(2):108-113. doi: 10.1016/j.hjc.2017.12.010. [PMID: 29305902]
  • Carlo Massimetti, Gea Imperato, Sandro Feriozzi. [Correction of secondary hyperparathyroidism with paricalcitol in renal transplant improves left ventricular hypertrophy]. Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia. 2019 Feb; 36(1):. doi: . [PMID: 30758155]
  • Tong Zhang, Hongbo Ju, Haojun Chen, Wen Wen. Comparison of Paricalcitol and Calcitriol in Dialysis Patients With Secondary Hyperparathyroidism: A Meta-Analysis of Randomized Controlled Studies. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 2019 Feb; 23(1):73-79. doi: 10.1111/1744-9987.12760. [PMID: 30328270]
  • Jung Sun Park, Hoon In Choi, Eun Hui Bae, Seong Kwon Ma, Soo Wan Kim. Paricalcitol attenuates indoxyl sulfate-induced apoptosis through the inhibition of MAPK, Akt, and NF-kB activation in HK-2 cells. The Korean journal of internal medicine. 2019 Jan; 34(1):146-155. doi: 10.3904/kjim.2016.298. [PMID: 28992684]
  • Osama M Ahmed, Tarek M Ali, Mohamed A Abdel Gaid, Ahmed A Elberry. Effects of enalapril and paricalcitol treatment on diabetic nephropathy and renal expressions of TNF-α, p53, caspase-3 and Bcl-2 in STZ-induced diabetic rats. PloS one. 2019; 14(9):e0214349. doi: 10.1371/journal.pone.0214349. [PMID: 31527864]
  • Brian Czaya, Wacharee Seeherunvong, Saurav Singh, Christopher Yanucil, Phillip Ruiz, Yasmir Quiroz, Alexander Grabner, Chryso Katsoufis, Sethuraman Swaminathan, Carolyn Abitbol, Bernardo Rodriguez-Iturbe, Christian Faul, Michael Freundlich. Cardioprotective Effects of Paricalcitol Alone and in Combination With FGF23 Receptor Inhibition in Chronic Renal Failure: Experimental and Clinical Studies. American journal of hypertension. 2019 01; 32(1):34-44. doi: 10.1093/ajh/hpy154. [PMID: 30329020]
  • Yang Liu, Ling-Yun Liu, Ye Jia, Mei-Yan Wu, Yan-Yan Sun, Fu-Zhe Ma. Efficacy and safety of paricalcitol in patients undergoing hemodialysis: a meta-analysis. Drug design, development and therapy. 2019; 13(?):999-1009. doi: 10.2147/dddt.s176257. [PMID: 30992658]
  • Manca Oblak, Gregor Mlinšek, Aljoša Kandus, Jadranka Buturović-Ponikvar, Miha Arnol. Paricalcitol versus placebo for reduction of proteinuria in kidney transplant recipients: a double-blind, randomized controlled trial. Transplant international : official journal of the European Society for Organ Transplantation. 2018 12; 31(12):1391-1404. doi: 10.1111/tri.13323. [PMID: 30062716]
  • Belinda Spoto, Patrizia Pizzini, Giovanni Tripepi, Francesca Mallamaci, Carmine Zoccali. Circulating adiponectin modifies the FGF23 response to vitamin D receptor activation: a post hoc analysis of a double-blind, randomized clinical trial. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2018 10; 33(10):1764-1769. doi: 10.1093/ndt/gfx344. [PMID: 29304245]
  • Marc Vila Cuenca, Evelina Ferrantelli, Elisa Meinster, Stephan M Pouw, Igor Kovačević, Renee X de Menezes, Hans W Niessen, Robert H J Beelen, Peter L Hordijk, Marc G Vervloet. Vitamin D Attenuates Endothelial Dysfunction in Uremic Rats and Maintains Human Endothelial Stability. Journal of the American Heart Association. 2018 09; 7(17):e008776. doi: 10.1161/jaha.118.008776. [PMID: 30371149]
  • X Hu, J Shang, W Yuan, S Zhang, Y Jiang, B Zhao, Y Duan, J Xiao, Z Zhao. Effects of paricalcitol on cardiovascular outcomes and renal function in patients with chronic kidney disease : A meta-analysis. Herz. 2018 Sep; 43(6):518-528. doi: 10.1007/s00059-017-4605-y. [PMID: 28835982]
  • Amin Ussif, Hege Pihlstrøm, Andreas Pasch, Hallvard Holdaas, Anders Hartmann, Knut Smerud, Anders Åsberg. Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score. BMC nephrology. 2018 08; 19(1):212. doi: 10.1186/s12882-018-1000-8. [PMID: 30134956]
  • Karima Farhat, Andrea W D Stavenuiter, Marc G Vervloet, Pieter M Ter Wee, Robert H J Beelen, Frans J van Ittersum. Effects of Oral Paricalcitol and Calcitriol Treatment on Peritoneal Membrane Characteristics of Peritoneal Dialysis Patients - A Pilot Study. Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis. 2018 May; 38(3):220-228. doi: 10.3747/pdi.2017.00150. [PMID: 29386308]
  • B Spoto, P Pizzini, S Cutrupi, G Tripepi, G Curatola, F Mallamaci, C Zoccali. Vitamin D receptor activation by paricalcitol and insulin resistance in CKD. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2018 03; 28(3):291-297. doi: 10.1016/j.numecd.2017.11.010. [PMID: 29307660]
  • T M Ali, B El Esawy, A Elaskary. Effect of paricalcitol on pancreatic oxidative stress, inflammatory markers, and glycemic status in diabetic rats. Irish journal of medical science. 2018 Feb; 187(1):75-84. doi: 10.1007/s11845-017-1635-7. [PMID: 28551720]
  • Aneliya Parvanova, Matias Trillini, Manuel A Podestà, Ilian Petrov Iliev, Barbara Ruggiero, Manuela Abbate, Annalisa Perna, Francesco Peraro, Olimpia Diadei, Nadia Rubis, Flavio Gaspari, Fabiola Carrara, Nadia Stucchi, Antonio Belviso, Antonio C Bossi, Roberto Trevisan, Giuseppe Remuzzi, Martin de Borst, Piero Ruggenenti. Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial. The lancet. Diabetes & endocrinology. 2018 01; 6(1):27-40. doi: 10.1016/s2213-8587(17)30359-5. [PMID: 29104158]
  • Teresa Jerónimo, Anabela Malho Guedes, Gloria Del Peso, Ana Paula Silva, Rafael Selgas, Maria Auxiliadora Bajo, Pedro Leão Neves. Paricalcitol and Peritoneal Protein Loss in Peritoneal Dialysis: A Double-Center Study. Blood purification. 2018; 46(2):103-110. doi: 10.1159/000488637. [PMID: 29672317]
  • I Dedinska, L Laca, J Miklusica, B Palkoci, P Skalova, D Kantarova, P Galajda, M Mokan. The role of proteinuria, paricalcitol and vitamin D in the development of post-transplant diabetes mellitus. Bratislavske lekarske listy. 2018 ; 119(7):401-407. doi: 10.4149/bll_2018_073. [PMID: 30160127]
  • Jacek Zawierucha, Jolanta Małyszko, Jacek S Małyszko, Tomasz Prystacki, Wojciech Marcinkowski, Teresa Dryl-Rydzyńska. Treatment of secondary hyperparathyroidism with paricalcitol with or without cinacalcet in hemodialysis patients. Polish archives of internal medicine. 2017 12; 127(12):840-845. doi: 10.20452/pamw.4124. [PMID: 29067991]
  • Longchuan Yu, James E Tomlinson, Shawn T Alexander, Kelly Hensley, Chun-Ya Han, Denise Dwyer, Marina Stolina, Charles Dean, William G Goodman, William G Richards, Xiaodong Li. Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism. Calcified tissue international. 2017 12; 101(6):641-653. doi: 10.1007/s00223-017-0319-7. [PMID: 29038882]
  • Zuzana Žilinská, Ivana Dedinská, Ján Breza, Ludovít Laca. Effect of Paricalcitol on Bone Density After Kidney Transplantation: Analysis of 2 Transplant Centers. Iranian journal of kidney diseases. 2017 Nov; 11(6):461-466. doi: . [PMID: 29190607]
  • Sara Panizo, Natalia Carrillo-López, Manuel Naves-Díaz, Guillermo Solache-Berrocal, Laura Martínez-Arias, Raúl R Rodrigues-Díez, Amalia Fernández-Vázquez, Carlos Martínez-Salgado, Marta Ruiz-Ortega, Adriana Dusso, Jorge B Cannata-Andía, Isabel Rodríguez. Regulation of miR-29b and miR-30c by vitamin D receptor activators contributes to attenuate uraemia-induced cardiac fibrosis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2017 Nov; 32(11):1831-1840. doi: 10.1093/ndt/gfx060. [PMID: 28460073]
  • Javier Donate-Correa, Fernando Henríquez-Palop, Ernesto Martín-Núñez, Carolina Hernández-Carballo, Carla Ferri, Nayra Pérez-Delgado, Mercedes Muros-de-Fuentes, Carmen Mora-Fernández, Juan F Navarro-González. Anti-inflammatory profile of paricalcitol in kidney transplant recipients. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 2017 Nov; 37(6):622-629. doi: 10.1016/j.nefro.2017.03.028. [PMID: 28623033]
  • Cynthia Ritter, Brent Miller, Daniel W Coyne, Diptesh Gupta, Sijie Zheng, Alex J Brown, Eduardo Slatopolsky. Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease. Kidney international. 2017 11; 92(5):1217-1222. doi: 10.1016/j.kint.2017.05.003. [PMID: 28750928]
  • Sibel Ersan, Asli Celik, Mehmet Tanrisev, Isil Kose, Zahide Cavdar, Mehtat Unlu, Ayse Kocak, Cemre Ural, Banu Yilmaz, Timur Kose. Pretreatment with paricalcitol attenuates level and expression of matrix metalloproteinases in a rat model of renal ischemia-reperfusion injury
. Clinical nephrology. 2017 Nov; 88(11):231-238. doi: 10.5414/cn109121. [PMID: 28737133]
  • Ourania Trohatou, Effie-Fotini Tsilibary, Aristidis Charonis, Christos Iatrou, Garyfalia Drossopoulou. Vitamin D3 ameliorates podocyte injury through the nephrin signalling pathway. Journal of cellular and molecular medicine. 2017 10; 21(10):2599-2609. doi: 10.1111/jcmm.13180. [PMID: 28664547]
  • Nicholas Obermüller, Alexander R Rosenkranz, Hans-Walter Müller, Dennis Hidde, András Veres, Sabine Decker-Burgard, Isolde Weisz, Helmut Geiger. Long-Term Therapy Outcomes When Treating Chronic Kidney Disease Patients with Paricalcitol in German and Austrian Clinical Practice (TOP Study). International journal of molecular sciences. 2017 Sep; 18(10):. doi: 10.3390/ijms18102057. [PMID: 28956807]
  • Katarina Mirkovic, Anne-Roos S Frenay, Jacob van den Born, Harry van Goor, Gerjan Navis, Martin H de Borst. Sodium restriction potentiates the renoprotective effects of combined vitamin D receptor activation and angiotensin-converting enzyme inhibition in established proteinuric nephropathy. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2017 Aug; 32(8):1293-1301. doi: 10.1093/ndt/gfv304. [PMID: 26311058]
  • Hege Kampen Pihlstrøm, Franscesca Gatti, Clara Hammarström, Ivar Anders Eide, Monika Kasprzycka, Junbai Wang, Guttorm Haraldsen, My Hanna Sofia Svensson, Karsten Midtvedt, Geir Mjøen, Dag Olav Dahle, Anders Hartmann, Hallvard Holdaas. Early introduction of oral paricalcitol in renal transplant recipients. An open-label randomized study. Transplant international : official journal of the European Society for Organ Transplantation. 2017 Aug; 30(8):827-840. doi: 10.1111/tri.12973. [PMID: 28436117]
  • Michael Freundlich, Carolyn L Abitbol. Oral paricalcitol: expanding therapeutic options for pediatric chronic kidney disease patients. Pediatric nephrology (Berlin, Germany). 2017 07; 32(7):1103-1108. doi: 10.1007/s00467-017-3675-7. [PMID: 28451892]
  • Nicholas J A Webb, Gary Lerner, Bradley A Warady, Katherine M Dell, Larry A Greenbaum, Gema Ariceta, Bernd Hoppe, Peter Linde, Ho-Jin Lee, Ann Eldred, Matthew B Dufek. Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease. Pediatric nephrology (Berlin, Germany). 2017 Jul; 32(7):1221-1232. doi: 10.1007/s00467-017-3579-6. [PMID: 28332096]
  • Julio M Martínez-Moreno, Carmen Herencia, Addy Montes de Oca, Juan M Díaz-Tocados, Noemi Vergara, M José Gómez-Luna, Silvia D López-Argüello, Antonio Camargo, Esther Peralbo-Santaella, Maria E Rodríguez-Ortiz, Antonio Canalejo, Mariano Rodríguez, Juan R Muñoz-Castañeda, Yolanda Almadén. High phosphate induces a pro-inflammatory response by vascular smooth muscle cells and modulation by vitamin D derivatives. Clinical science (London, England : 1979). 2017 Jul; 131(13):1449-1463. doi: 10.1042/cs20160807. [PMID: 28442557]
  • Tajda Keber, Martin Tretjak, Andreja Cokan Vujkovac, Marija Mravljak, Katja Ravber, Bojan Vujkovac. Paricalcitol as an Antiproteinuric Agent Can Result in the Deterioration of Renal and Heart Function in a Patient with Fabry Disease. The American journal of case reports. 2017 Jun; 18(?):644-648. doi: 10.12659/ajcr.903886. [PMID: 28596512]
  • Ladan Mansouri, Kristina Lundwall, Ali Moshfegh, Stefan H Jacobson, Joachim Lundahl, Jonas Spaak. Vitamin D receptor activation reduces inflammatory cytokines and plasma MicroRNAs in moderate chronic kidney disease - a randomized trial. BMC nephrology. 2017 May; 18(1):161. doi: 10.1186/s12882-017-0576-8. [PMID: 28511692]
  • Saleh Yazdani, Fariba Poosti, Luis Toro, Johannes Wedel, Rik Mencke, Katarina Mirković, Martin H de Borst, J Steven Alexander, Gerjan Navis, Harry van Goor, Jacob van den Born, Jan-Luuk Hillebrands. Vitamin D inhibits lymphangiogenesis through VDR-dependent mechanisms. Scientific reports. 2017 03; 7(?):44403. doi: 10.1038/srep44403. [PMID: 28303937]
  • C Torino, P Pizzini, S Cutrupi, G Tripepi, F Mallamaci, R Thadhani, C Zoccali. Active vitamin D treatment in CKD patients raises serum sclerostin and this effect is modified by circulating pentosidine levels. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2017 Mar; 27(3):260-266. doi: 10.1016/j.numecd.2016.11.005. [PMID: 28017524]
  • Hideki Fujii, Yuriko Yonekura, Kentaro Nakai, Keiji Kono, Shunsuke Goto, Shinichi Nishi. Comparison of the effects of novel vitamin D receptor analog VS-105 and paricalcitol on chronic kidney disease-mineral bone disorder in an experimental model of chronic kidney disease. The Journal of steroid biochemistry and molecular biology. 2017 03; 167(?):55-60. doi: 10.1016/j.jsbmb.2016.11.002. [PMID: 27818277]
  • Kaichiro Sawada, J Ruth Wu-Wong, Yung-Wu Chen, Jerry L Wessale, Genta Kanai, Takatoshi Kakuta, Masafumi Fukagawa. Vitamin D receptor agonist VS-105 directly modulates parathyroid hormone expression in human parathyroid cells and in 5/6 nephrectomized rats. The Journal of steroid biochemistry and molecular biology. 2017 03; 167(?):48-54. doi: 10.1016/j.jsbmb.2016.10.008. [PMID: 27989797]
  • Lucia Spath, Alessandra Ulivieri, Luca Lavra, Laura Fidanza, Marta Carlesimo, Maria Giubettini, Alessandra Narcisi, Emidio Luciani, Barbara Bucci, Daniela Pisani, Salvatore Sciacchitano, Armando Bartolazzi. Antiproliferative Effects of 1α-OH-vitD3 in Malignant Melanoma: Potential Therapeutic implications. Scientific reports. 2017 01; 7(?):40370. doi: 10.1038/srep40370. [PMID: 28074906]
  • Yu Ah Hong, Keum Jin Yang, So Young Jung, Ki Cheol Park, Hyunsu Choi, Jeong Min Oh, Sang Ju Lee, Yoon Kyung Chang, Cheol Whee Park, Chul Woo Yang, Suk Young Kim, Hyeon Seok Hwang. Paricalcitol Pretreatment Attenuates Renal Ischemia-Reperfusion Injury via Prostaglandin E2 Receptor EP4 Pathway. Oxidative medicine and cellular longevity. 2017; 2017(?):5031926. doi: 10.1155/2017/5031926. [PMID: 28465762]
  • Manca Oblak, Gregor Mlinšek, Aljoša Kandus, Jadranka Buturović-Ponikvar, Miha Arnol. Effects of paricalcitol on biomarkers of inflammation and fibrosis in kidney transplant recipients: results of a randomized controlled trial. Clinical nephrology. 2017 Sup; 88(13):119-125. doi: 10.5414/cnp88fx26. [PMID: 28664839]
  • Jonay Poveda, Ana B Sanz, Beatriz Fernandez-Fernandez, Susana Carrasco, Marta Ruiz-Ortega, Pablo Cannata-Ortiz, Alberto Ortiz, Maria D Sanchez-Niño. MXRA5 is a TGF-β1-regulated human protein with anti-inflammatory and anti-fibrotic properties. Journal of cellular and molecular medicine. 2017 01; 21(1):154-164. doi: 10.1111/jcmm.12953. [PMID: 27599751]
  • Sungjin Chung, Soojeong Kim, Minyoung Kim, Eun Sil Koh, Seok Joon Shin, Cheol Whee Park, Yoon Sik Chang, Ho-Shik Kim. Treatment combining aliskiren with paricalcitol is effective against progressive renal tubulointerstitial fibrosis via dual blockade of intrarenal renin. PloS one. 2017; 12(7):e0181757. doi: 10.1371/journal.pone.0181757. [PMID: 28753620]
  • Jia Guo, Congqun Lu, Fangxing Zhang, Haixia Yu, Mengwen Zhou, Meixia He, Chunyan Wang, Zhanzheng Zhao, Zhangsuo Liu. VDR Activation Reduces Proteinuria and High-Glucose-Induced Injury of Kidneys and Podocytes by Regulating Wnt Signaling Pathway. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2017; 43(1):39-51. doi: 10.1159/000480315. [PMID: 28848172]
  • Claudia Torino, Patrizia Pizzini, Sebastiano Cutrupi, Rocco Tripepi, Giovanni Tripepi, Francesca Mallamaci, Carmine Zoccali. Vitamin D and methylarginines in chronic kidney disease (CKD). PloS one. 2017; 12(10):e0185449. doi: 10.1371/journal.pone.0185449. [PMID: 28976989]
  • Claudia Torino, Patrizia Pizzini, Sebastiano Cutrupi, Rocco Tripepi, Antonio Vilasi, Giovanni Tripepi, Francesca Mallamaci, Carmine Zoccali. Effect of Vitamin D Receptor Activation on the AGE/RAGE System and Myeloperoxidase in Chronic Kidney Disease Patients. Oxidative medicine and cellular longevity. 2017; 2017(?):2801324. doi: 10.1155/2017/2801324. [PMID: 29362665]
  • Jing-Quan Zheng, Yi-Chou Hou, Cai-Mei Zheng, Chien-Lin Lu, Wen-Chih Liu, Chia-Chao Wu, Ming-Te Huang, Yuh-Feng Lin, Kuo-Cheng Lu. Cholecalciferol Additively Reduces Serum Parathyroid Hormone and Increases Vitamin D and Cathelicidin Levels in Paricalcitol-Treated Secondary Hyperparathyroid Hemodialysis Patients. Nutrients. 2016 Nov; 8(11):. doi: 10.3390/nu8110708. [PMID: 27827962]
  • Javier Donate-Correa, Fernando Henríquez-Palop, Ernesto Martín-Núñez, Nayra Pérez-Delgado, Mercedes Muros-de-Fuentes, Carmen Mora-Fernández, Juan F Navarro-González. Effect of Paricalcitol on FGF-23 and Klotho in Kidney Transplant Recipients. Transplantation. 2016 Nov; 100(11):2432-2438. doi: 10.1097/tp.0000000000001339. [PMID: 27467536]
  • Yiğit Uyanıkgil, Volkan Solmaz, Türker Çavuşoğlu, Bilge Piri Çınar, Emel Öykü Çetin, Halil Yılmaz Sur, Oytun Erbaş. Inhibitor effect of paricalcitol in rat model of pentylenetetrazol-induced seizures. Naunyn-Schmiedeberg's archives of pharmacology. 2016 Oct; 389(10):1117-22. doi: 10.1007/s00210-016-1273-z. [PMID: 27438482]
  • Masahide Mizobuchi, Hiroaki Ogata, Ai Yamazaki-Nakazawa, Nozomu Hosaka, Fumiko Kondo, Fumihiko Koiwa, Eriko Kinugasa, Takanori Shibata. Cardiac effect of vitamin D receptor modulators in uremic rats. The Journal of steroid biochemistry and molecular biology. 2016 10; 163(?):20-7. doi: 10.1016/j.jsbmb.2016.03.028. [PMID: 27072785]
  • Chi-Cheng Lai, Chun-Peng Liu, Pei-Wen Cheng, Pei-Jung Lu, Michael Hsiao, Wen-Hsien Lu, Gwo-Ching Sun, Jau-Cheng Liou, Ching-Jiunn Tseng. Paricalcitol Attenuates Cardiac Fibrosis and Expression of Endothelial Cell Transition Markers in Isoproterenol-Induced Cardiomyopathic Rats. Critical care medicine. 2016 09; 44(9):e866-74. doi: 10.1097/ccm.0000000000001736. [PMID: 27065465]
  • Luis Manjarres, Pilar Sanchez, María C Cabezas, Marco Fornasini, Valeria Freire, Adelin Albert. Budget impact of secondary hyperparathyroidism treatment in chronic kidney disease in an Ecuadorian social security hospital. BMC health services research. 2016 08; 16(?):443. doi: 10.1186/s12913-016-1671-4. [PMID: 27566059]
  • Julio E Pena-Polanco, Linda F Fried. Established and Emerging Strategies in the Treatment of Chronic Kidney Disease. Seminars in nephrology. 2016 07; 36(4):331-42. doi: 10.1016/j.semnephrol.2016.05.009. [PMID: 27475663]
  • C Zoccali, C Torino, G Curatola, V Panuccio, R Tripepi, P Pizzini, M Versace, D Bolignano, S Cutrupi, L Ghiadoni, R Thadhani, G Tripepi, F Mallamaci. Serum phosphate modifies the vascular response to vitamin D receptor activation in chronic kidney disease (CKD) patients. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2016 07; 26(7):581-589. doi: 10.1016/j.numecd.2016.03.008. [PMID: 27113290]
  • Inés Olaizola, Hena Caorsi, Laura Fajardo, Alejandro Ferreiro, Nieves Campistrus, Deyanira Dolinsky, Alicia Petraglia, Pablo Ambrosoni. Effectiveness and safety of a 6-month treatment with paricalcitol in patients on hemodialysis with secondary hyperparathyroidism. Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia. 2016 Jul; 38(3):302-312. doi: 10.5935/0101-2800.20160047. [PMID: 27737388]
  • Jennifer Kumar, Ngoc-Tram Gia Tran, John Schomberg, Elani Streja, Kamyar Kalantar-Zadeh, Madeleine Pahl. Successful Conversion From Parenteral Paricalcitol to Pulse Oral Calcitriol for the Management of Secondary Hyperparathyroidism in Hemodialysis Patients. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation. 2016 07; 26(4):265-9. doi: 10.1053/j.jrn.2016.02.006. [PMID: 27038806]
  • Fabiana Gatti de Menezes, Rodrigo Martins Abreu, Alexander Itria. Cost-effectiveness analysis of paricalcitol versus calcitriol for the treatment of SHPT in dialytic patients from the SUS perspective. Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia. 2016 Jul; 38(3):313-319. doi: 10.5935/0101-2800.20160048. [PMID: 27737389]
  • Arend Jan Nieuwland, Vivianne Bc Kokje, Olivier H Koning, Jaap F Hamming, Karoly Szuhai, Frans H J Claas, Jan H N Lindeman. Activation of the vitamin D receptor selectively interferes with calcineurin-mediated inflammation: a clinical evaluation in the abdominal aortic aneurysm. Laboratory investigation; a journal of technical methods and pathology. 2016 07; 96(7):784-90. doi: 10.1038/labinvest.2016.55. [PMID: 27239732]